Esperion Therapeutis.Inc. buy dartajon99
Start price
22.05.23
/
50%
€1.53
Target price
22.06.23
-
Performance (%)
-17.49%
End price
23.06.23
€1.26
Summary
This prediction ended on 23.06.23 with a price of €1.26. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -17.49%. dartajon99 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 3.723% | 3.723% | 93.037% |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% |
According to dartajon99 what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by dartajon99 for this prediction
In the thread Trading Esperion Therapeutis.Inc.
Die von dartajon99 gewählte maximale Laufzeit wurde überschritten
